The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung

被引:5
|
作者
Bulutay, Pinar [1 ]
Firat, Pinar [1 ]
Zeren, Handan [2 ]
Erus, Suat [3 ]
Tanju, Serhan [3 ]
Dilege, Sukru [3 ]
机构
[1] Koc Univ, Med Fac, Dept Pathol, Istanbul, Turkey
[2] Acibadem Univ, Med Fac, Dept Pathol, Istanbul, Turkey
[3] Koc Univ, Med Fac, Dept Thorac Surg, Istanbul, Turkey
关键词
PD-L1; lung cancer; immunotherapy; lung adenocarcinoma; IMMUNE CELLS; EXPRESSION; CANCER; IMMUNOHISTOCHEMISTRY; CLASSIFICATION; IMMUNOTHERAPY; RELIABILITY; ANTI-PD-1; LIGANDS;
D O I
10.3906/sag-2004-61
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aim: Programmed death ligand-1 (PD-L1) is a predictive marker for immunotherapeutic agents. However, heterogeneous staining of PD-L1 can cause false-negative results. The aim of this study is to evaluate the importance of histological patterns on PD-L1 staining heterogeneity in lung adenocarcinomas (LAC). Materials and methods: PD-L1 immunohistochemistry (IHC) stain was performed to two different tissue cores of 128 LAC cases, and cut-off values are given for grouping the cases according to the percentage of staining (1%-10%, 11%-49%, 50%-100%). Staining rates between cores were compared and analyzed by their histological patterns. Also, the relation of the PD-L1 expression with the clinicopathological characteristics of the cases was analyzed. Results: Overall, PD-L1 expression was observed in 53 of 128 cases (41.4%, 1% cut-off), 23.5% of them were positive at 10% cut-off and 14.1% at 50% cut-off. PD-L1 expression was significantly related to the high grade micropapillary and solid patterns of adenocarcinomas (p:0.01). Staining cut-offs were mostly similar between cores (43/50, 86%) (k:0.843). However, 14% of them were positive only in one core (7 of 50). This false negativity was mostly related to the histological patterns. Conclusion: Our data reveal the heterogeneous staining of PD-L1 expression, also micropapillary and solid patterns show higher rates of PDL expression. Therewithal, these findings also highlight the importance of taking into consideration of histological patterns, when choosing a paraffin block for the PDL1.
引用
收藏
页码:204 / 213
页数:10
相关论文
共 50 条
  • [1] Accuracy of PD-L1 tumour staining of cytological and histological samples of lung adenocarcinoma
    Wagner, Carrie-Anne
    Christie, Michael
    Irving, Louis
    Steinfort, Daniel
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [2] p40/PD-L1 and TTF1/PD-L1 Immunohistochemical Double Staining Contributes to Intraindividual Variability Associated With PD-L1 Staining Interpretation in Lung Cancer Samples
    Campelos, Sofia
    Polonia, Antonio
    Caramelo, Ana
    Curado, Monica
    Eloy, Catarina
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2022, 30 (03) : 165 - 170
  • [3] Heterogeneity and Geographical Patterns of PD-L1 Expression in Colonic Adenocarcinoma with Discordant PD-L1 Status
    Messersmith, Lynn
    Williams, Grant
    Bohan, Phillip Kemp
    Chick, Robert
    Broadwater, Devin
    Lombardo, Jamie
    Hickerson, Annelies
    Cindass, Jessica
    Brady, Robert
    Peoples, George
    Clifton, Guy
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 716 - 717
  • [4] Heterogeneity and Geographical Patterns of PD-L1 Expression in Colonic Adenocarcinoma with Discordant PD-L1 Status
    Messersmith, Lynn
    Williams, Grant
    Bohan, Phillip Kemp
    Chick, Robert
    Broadwater, Devin
    Lombardo, Jamie
    Hickerson, Annelies
    Cindass, Jessica
    Brady, Robert
    Peoples, George
    Clifton, Guy
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 716 - 717
  • [5] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Katerina Ancevski Hunter
    Mark A. Socinski
    Liza C. Villaruz
    Molecular Diagnosis & Therapy, 2018, 22 : 1 - 10
  • [6] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Hunter, Katerina Ancevski
    Socinski, Mark A.
    Villaruz, Liza C.
    MOLECULAR DIAGNOSIS & THERAPY, 2018, 22 (01) : 1 - 10
  • [7] Tumor-derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer
    Wu, Yunjiao
    Fu, Huichao
    Hao, Jingwei
    Yang, Zhaoyang
    Qiao, Xinyi
    Li, Yingjie
    Zhao, Rui
    Lin, Tie
    Wang, Yicun
    Wang, Meng
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [8] PD-1 and PD-L1 staining patterns in cervical squamous cell carcinoma
    Hodeib, M.
    Lester, J.
    Laury, A.
    Cass, I.
    Rimel, B. J.
    Li, A. J.
    Karlan, B. Y.
    Walsh, C. S.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (01) : 210 - 210
  • [9] Assessment of PD-L1 Expression in Gastric Tumor Samples
    Scorer, P.
    Barker, C.
    Scott, M.
    Li, W.
    Rebelatto, M.
    Walker, J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (11): : S61 - S61
  • [10] PD-L1 testing in urothelial carcinoma: are we there yet?
    van Leenders, Geert J. L. H.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 : S466 - S468